Lissette Selem, MD
Psychiatry · Miami Lakes, FLNPI 1093910499
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 644 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 644 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$732
- plus $3K from 14 others
Across 287 payments — averaging $5586.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$770K
- Janssen Research & Development, LLC$385K
- Eli Lilly$171K
- Jazz Pharmaceuticals Inc.$129K
- Acadia Pharmaceuticals Inc$105K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- plus $22K from 3 others
What the payments were for
- Food & beverage$12,47998%
- Education$2222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 123 | $2,448 |
| AbbVie(2 entities) | 124 | $2,249 |
| Sunovion Pharmaceuticals Inc. | 117 | $2,035 |
| Otsuka America Pharmaceutical, Inc. | 85 | $1,576 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $1,032 |
| Neurocrine Biosciences, Inc. | 30 | $732 |
| Lundbeck LLC | 25 | $538 |
| Vanda Pharmaceuticals Inc. | 24 | $516 |
| Alkermes, Inc. | 23 | $500 |
| Axsome Therapeutics, Inc. | 12 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $241 |
| E.r. Squibb & Sons, L.L.C. | 6 | $167 |
| Johnson & Johnson | 4 | $74 |
| Tris Pharma Inc | 3 | $73 |
| Almatica Pharma LLC | 2 | $48 |
| Avanir Pharmaceuticals, Inc. | 2 | $47 |
| Noven Therapeutics, LLC | 2 | $36 |
| Tempus AI, Inc | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$513
- LATUDA$234
- Austedo XR$115
How this compares
$12,702 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorpromazine Hcl | 296 | $173,159 |
| IngrezzaValbenazine Tosylate | 13 | $101,799 |
| Risperdal ConstaRisperidone Microspheres | 19 | $35,946 |
| FanaptIloperidone | 12 | $28,677 |
| VraylarCariprazine Hcl | 16 | $24,506 |
| Quetiapine Fumarate | 795 | $21,814 |
| TrintellixVortioxetine Hydrobromide | 29 | $15,146 |
| Divalproex Sodium | 410 | $14,425 |
| RisperdalRisperidone | 20 | $12,757 |
| Olanzapine | 279 | $11,519 |
| Aripiprazole | 181 | $10,012 |
| Trazodone Hcl | 461 | $8,819 |
| Lurasidone Hcl | 78 | $8,362 |
| Oxcarbazepine | 103 | $7,788 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 96 | $7,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $732 | $101,79913 claims |
| Johnson & JohnsonRisperdal Consta, Risperdal, Invega | $74 | $56,38557 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $516 | $28,67712 claims |
| AbbVieVraylar | $2,249 | $24,50616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $241 | $15,14629 claims |
| Almatica Pharma LLCSertraline Hcl | $48 | $5,487547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami Lakes
- Maribel AguileraMiami Lakes$118K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.